Tyrosine News and Research

RSS

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Pre-eclampsia is a serious illness associated with pregnancy, which develops after twenty weeks and is associated with defective ingrowing of the placenta within the mother. The dangerous illness is both the second most frequent cause of death in pregnant women, and the reason for severe complications for mother and child, especially during premature births.

25 Jan 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

22 Jan 2016

BCR–ABL transcript type linked to TKI response, outcomes

The type of BCR–ABL transcript could have an impact on tyrosine kinase inhibitor choice in patients with chronic myeloid leukaemia , according to research published in Blood.

22 Jan 2016

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.

21 Dec 2015

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Converting white fat cells into beige fat cells could help fight obesity

The body's ability to harness heat production by converting white fat cells, which store calories, into beige fat cells, which burn energy, could help fight obesity, according to researchers at Georgia State University.

17 Dec 2015

$Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma$

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Phase III trial findings suggest that patients with relapsed or refractory mantle cell lymphoma derive significantly greater benefits from ibrutinib than from temsirolimus therapy.

14 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

The combination of ibrutinib and rituximab shows activity in patients with relapsed or refractory mantle cell lymphoma, suggests research published in The Lancet Oncology.

2 Dec 2015

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).

1 Dec 2015

Ultra-performance chromatography test aids bosutinib plasma quantification

Chinese scientists have developed a fast and sensitive method for the quantification of the tyrosine kinase inhibitor bosutinib in rat blood samples.

27 Nov 2015

Tyrosine News and Research

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Positive bosutinib response for elderly blast phase CML patient

Cardiovascular considerations crucial for CML TKI patients

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

BCR–ABL transcript type linked to TKI response, outcomes

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Converting white fat cells into beige fat cells could help fight obesity

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

New approaches to treating leukemia, lymphoma and myeloma

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Ultra-performance chromatography test aids bosutinib plasma quantification

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News